Oxurion NV OXUR.BR · Stock Open Oxurion NV in new tab
Oxurion NV Analysis (OXUR.BR)
Is Oxurion NV a good investment? Oxurion NV (OXUR.BR) is currently trading at 0.002800 EUR.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Oxurion NV is undervalued compared to historical market norms.
Earnings Schedule: Oxurion NV is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.47.
Investor FAQ
Does Oxurion NV pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oxurion NV?
Oxurion NV is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of 2.23.
Company Profile
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 3, 2024 | 1:10000 |
Community Discussion